CYP450 Genotype and Pharmacogenetic Association Studies: a Critical Appraisal

References

• Roden DM , XuH , DennyJC , WilkeRA . Electronic medical records as a tool in clinical pharmacology: opportunities and challenges . Clin. Pharmacol. Ther.91 ( 6 ), 1083 – 1086 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Sallustio BC , WestleyIS , MorrisRG . Pharmacokinetics of the antianginal agent perhexiline: relationship between metabolic ratio and steady-state dose . Br. J. Clin. Pharmacol.54 ( 2 ), 107 – 114 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Barclay ML , SawyersSM , BeggEJet al. Correlation of CYP2D6 genotype with perhexiline phenotypic metabolizer status . Pharmacogenetics13 ( 10 ), 627 – 632 ( 2003 ).
   PubMedGoogle Scholar
• Killalea SM , KrumH . Systematic review of the efficacy and safety of perhexiline in the treatment of ischemic heart disease . Am. J. Cardiovasc. Drugs1 ( 3 ), 193 – 204 ( 2001 ).
   PubMedGoogle Scholar
• Phan TT , ShivuGN , ChoudhuryAet al. Multi-centre experience on the use of perhexiline in chronic heart failure and refractory angina: old drug, new hope . Eur. J. Heart Fail.11 ( 9 ), 881 – 886 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Clinical Pharmacogenetics implementation consortium and Dutch pharmacogenetics working group . Pharmacogenetic dosing guidelines . www.pharmgkb.org/view/dosing-guidelines.do?source= .
   Google Scholar
• Innocenti F , UndeviaSD , IyerLet al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan . J. Clin. Oncol.22 ( 8 ), 1382 – 1388 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Goetz MP , RaeJM , SumanVJet al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes . J. Clin. Oncol.23 ( 36 ), 9312 – 9318 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Hulot JS , BuraA , VillardEet al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects . Blood108 ( 7 ), 2244 – 2247 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Anderson JL , HorneBD , StevensSMet al. for Couma-Gen Investigators . Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation . Circulation116 ( 22 ), 2563 – 2570 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Klein TE , AltmanRB , ErikssonNet al. for International Warfarin Pharmacogenetics Consortium . Estimation of the warfarin dose with clinical and pharmacogenetic data . N. Engl. J. Med.360 ( 8 ), 753 – 764 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Simon T , VerstuyftC , Mary-KrauseMet al. for French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators . Genetic determinants of response to clopidogrel and cardiovascular events . N. Engl. J. Med.360 ( 4 ), 363 – 375 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Schroth W , GoetzMP , HamannUet al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen . JAMA302 ( 13 ), 1429 – 1436 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Kimmel SE , FrenchB , KasnerSEet al. for COAG Investigators . A pharmacogenetic versus a clinical algorithm for warfarin dosing . N. Engl. J. Med.369 ( 24 ), 2283 – 2293 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Pirmohamed M , BurnsideG , ErikssonNet al. for EU-PACT Group . A randomized trial of genotype-guided dosing of warfarin . N. Engl. J. Med.369 ( 24 ), 2294 – 2303 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Verhoef TI , RagiaG , de BoerAet al. for EU-PACT Group . A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon . N. Engl. J. Med.369 ( 24 ), 2304 – 2312 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Rae JM , DruryS , HayesDFet al. for ATAC trialists . CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients . J. Natl Cancer Inst.104 ( 6 ), 452 – 460 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Vianna-Jorge R , Festa-VasconcellosJS , Goulart-CitranguloSM , LeiteMS . Functional polymorphisms in xenobiotic metabolizing enzymes and their impact on the therapy of breast cancer . Front. Genet.3 , 329 ( 2013 ).
   PubMedGoogle Scholar
• Lum DW , PerelP , HingoraniAD , HolmesMV . CYP2D6 genotype and tamoxifen response for breast cancer: a systematic review and meta-analysis . PLoS ONE8 ( 10 ), e76648 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Province MA , GoetzMP , BrauchHet al. for International Tamoxifen Pharmacogenomics Consortium . CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations . Clin. Pharmacol. Ther.95 ( 2 ), 216 – 227 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Osnabrugge RL , HeadSJ , ZijlstraFet al. A systematic review and critical assessment of 11 discordant meta-analyses on reduced-function CYP2C19 genotype and risk of adverse clinical outcomes in clopidogrel users . Genet. Med.17 ( 1 ), 3 – 11 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Sheikh AR , WestleyI , SallustioB , HorowitzJD , BeltrameJF . Interaction of terbinafine (anti-fungal agent) with perhexiline: a case report . Heart Lung Circ.23 ( 6 ), e149 – e151 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Nyfort-Hansen K . Perhexiline toxicity related to citalopram use . Med. J. Aust.176 ( 11 ), 560 – 561 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Zanger UM , KleinK , ThomasMet al. Genetics, epigenetics, and regulation of drug-metabolizing cytochrome p450 enzymes . Clin. Pharmacol. Ther.95 ( 3 ), 258 – 261 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• CYPalleles . www.cypalleles.ki.se/ .
   Google Scholar
• Zhou SF . Polymorphism of human cytochrome P450 2D6 and its clinical significance: part I . Clin. Pharmacokinet.48 ( 11 ), 689 – 723 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Zhou SF . Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II . Clin. Pharmacokinet.48 ( 12 ), 761 – 804 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Gaedigk A . Complexities of CYP2D6 gene analysis and interpretation . Int. Rev. Psychiatry25 ( 5 ), 534 – 553 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Cairns W , SmithCA , McLarenAW , WolfCR . Characterization of the human cytochrome P4502D6 promoter. A potential role for antagonistic interactions between members of the nuclear receptor family . J. Biol. Chem.271 ( 41 ), 25269 – 25276 ( 1996 ).
   PubMed Web of Science ®Google Scholar
• Gonzalez FJ . Regulation of hepatocyte nuclear factor 4 alpha-mediated transcription . Drug Metab. Pharmacokinet.23 ( 1 ), 2 – 7 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Topletz AR , LeHN , LeeNet al. Hepatic CYP2D and CYP26A1 mRNAs and activities are increased during mouse pregnancy . Drug Metab. Dispos.41 ( 2 ), 312 – 319 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Lee SS , ChaEY , JungHJet al. Genetic polymorphism of hepatocyte nuclear factor-4alpha influences human cytochrome P450 2D6 activity . Hepatology48 ( 2 ), 635 – 645 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Jiang F , YeoCW , LeeSSet al. Effect of HNF4α genetic polymorphism G60D on the pharmacokinetics of CYP2D6 substrate tolterodine in healthy Korean individuals . Pharmacogenet. Genomics23 ( 3 ), 175 – 179 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Ramamoorthy A , LiL , GaedigkAet al. In silico and in vitro identification of microRNAs that regulate hepatic nuclear factor 4α expression . Drug Metab. Dispos.40 ( 4 ), 726 – 733 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Clinical Pharmacogenetics Implementation Consortium. Clinical pharmacogenetics implementation consortium (CPIC) guidelines for cytochrome P450 2D6 (CYP2D6) genotype and codeine therapy: 2014 update . www.pharmgkb.org/guideline/PA166104996 .
   Google Scholar
• Dutch Pharmacogenetic Working Group . Genotype to phenotype translation. CYP2D6 genotype to phenotype (July 2009) . www.pharmgkb.org/page/dpwg .
   Google Scholar
• Hicks JK , SwenJJ , GaedigkA . Challenges in CYP2D6 phenotype assignment from genotype data: a critical assessment and call for standardization . Curr. Drug Metab.15 ( 2 ), 218 – 232 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Zineh I , BeitelsheesAL , GaedigkAet al. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension . Clin. Pharmacol. Ther.76 ( 6 ), 536 – 544 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Gaedigk A , SimonSD , PearceRE , BradfordLD , KennedyMJ , LeederJS . The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype . Clin. Pharmacol. Ther.83 ( 2 ), 234 – 242 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Kirchheiner J . CYP2D6 phenotype prediction from genotype: which system is the best?Clin. Pharmacol. Ther.83 ( 2 ), 225 – 227 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Alessandrini M , AsfahaS , DodgenTM , WarnichL , PepperMS . Cytochrome P450 pharmacogenetics in African populations . Drug Metab. Rev.45 ( 2 ), 253 – 275 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• LLerena A , NaranjoME , Rodrigues-SoaresF , Penas-LLedóEM , FariñasH , Tarazona-SantosE . Interethnic variability of CYP2D6 alleles and of predicted and measured metabolic phenotypes across world populations . Expert Opin. Drug Metab. Toxicol.10 ( 11 ), 1569 – 1583 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Griese EU , Asante-PokuS , Ofori-AdjeiD , MikusG , EichelbaumM . Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a west African population . Pharmacogenetics9 ( 6 ), 715 – 723 ( 1999 ).
   PubMedGoogle Scholar
• Gaedigk A , BradfordLD , MarcucciKA , LeederJS . Unique CYP2D6 activity distribution and genotype–phenotype discordance in black Americans . Clin. Pharmacol. Ther.72 ( 1 ), 76 – 89 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Montané Jaime LK , LallaA , SteimerW , GaedigkA . Characterization of the CYP2D6 gene locus and metabolic activity in Indo- and Afro-Trinidadians: discovery of novel allelic variants . Pharmacogenomics14 ( 3 ), 261 – 276 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Scott SA , JaremkoM , LubitzSA , KornreichR , HalperinJL , DesnickRJ . CYP2C9*8 is prevalent among African–Americans: implications for pharmacogenetic dosing . Pharmacogenomics10 ( 8 ), 1243 – 1255 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Drozda K , WongS , PatelSRet al. Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African–Americans . Pharmacogenet. Genomics25 ( 2 ), 73 – 81 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Dorado P , GallegoA , Peñas-LLedóE , TeránE , LLerenaA . Relationship between the CYP2C9 IVS8–109A>T polymorphism and high losartan hydroxylation in healthy Ecuadorian volunteers . Pharmacogenomics15 ( 11 ), 1417 – 1421 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Hatta FH , TehLK , HelldénAet al. Search for the molecular basis of ultra-rapid CYP2C9-catalysed metabolism: relationship between SNP IVS8–109A>T and the losartan metabolism phenotype in Swedes . Eur. J. Clin. Pharmacol.68 ( 7 ), 1033 – 1042 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Ortega-Vázquez A , DoradoP , Fricke-GalindoIet al. CYP2C9, CYP2C19, ABCB1 genetic polymorphisms and phenytoin plasma concentrations in Mexican-Mestizo patients with epilepsy . Pharmacogenomics J. doi:10.1038/tpj.2015.45 ( 2015 ) ( Epub ahead of print ).
   PubMed Web of Science ®Google Scholar
• Masimirembwa C , PerssonI , BertilssonL , HaslerJ , Ingelman-SundbergM . A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity . Br. J. Clin. Pharmacol.42 ( 6 ), 713 – 719 ( 1996 ).
   PubMed Web of Science ®Google Scholar
• Cai W-M , NikoloffDM , PanR-Met al. CYP2D6 genetic variation in healthy adults and psychiatric African–American subjects: implications for clinical practice and genetic testing . Pharmacogenomics J.6 ( 5 ), 343 – 350 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Woolhouse NM , EichelbaumM , OatesNS , IdleJR , SmithRL . Dissociation of co-regulatory control of debrisoquin/phenformin and sparteine oxidation in Ghanaians . Clin. Pharmacol. Ther.37 ( 5 ), 512 – 521 ( 1985 ).
   PubMed Web of Science ®Google Scholar
• Masimirembwa C , HaslerJ , BertilssonsL , JohanssonI , EkbergO , Ingelman-SundbergM . Phenotype and genotype analysis of debrisoquine hydroxylase (CYP2D6) in a black Zimbabwean population. Reduced enzyme activity and evaluation of metabolic correlation of CYP2D6 probe drugs . Eur. J. Clin. Pharmacol.51 ( 2 ), 117 – 122 ( 1996 ).
   PubMed Web of Science ®Google Scholar
• Muroi Y , SaitoT , TakahashiMet al. Functional characterization of wild-type and 49 CYP2D6 allelic variants for N-desmethyltamoxifen 4-hydroxylation activity . Drug Metab. Pharmacokinet.29 ( 5 ), 360 – 366 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Hertz DL , SnavelyAC , McLeodHLet al. In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles . Br. J. Clin. Pharmacol.80 ( 5 ), 1122 – 1130 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Raimundo S , ToscanoC , KleinKet al. A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects . Clin. Pharmacol. Ther.76 ( 2 ), 128 – 138 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Kumar V , WahlstromJL , RockDA , WarrenCJ , GormanLA , TracyTS . CYP2C9 inhibition: impact of probe selection and pharmacogenetics on in vitro inhibition profiles . Drug Metab. Dispos.34 ( 12 ), 1966 – 1975 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Shah RR , SmithRL . Addressing phenoconversion: the Achilles’ heel of personalized medicine . Br. J. Clin. Pharmacol.79 ( 2 ), 222 – 240 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Shah RR , SmithRL . Inflammation-induced phenoconversion of polymorphic drug metabolizing enzymes: hypothesis with implications for personalized medicine . Drug Metab. Dispos.43 ( 3 ), 400 – 410 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Preskorn SH , KaneCP , LobelloKet al. Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine . J. Clin. Psychiatry74 ( 6 ), 614 – 621 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Klieber M , OberacherH , HofstaetterSet al. Cytochrome P450 2C19 phenoconversion by routinely prescribed proton pump inhibitors omeprazole and esomeprazole: clinical implications for personalized medicine . J. Pharmacol. Exp. Ther.354 ( 3 ), 426 – 430 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Kotlyar M , BrauerLH , TracyTSet al. Inhibition of CYP2D6 activity by bupropion . J. Clin. Psychopharmacol.25 ( 3 ), 226 – 229 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Haefeli WE , BargetziMJ , FollathF , MeyerUA . Potent inhibition of cytochrome P450IID6 (debrisoquin 4-hydroxylase) by flecainide in vitro and In vivo . J. Cardiovasc. Pharmacol.15 ( 5 ), 776 – 779 ( 1990 ).
   PubMed Web of Science ®Google Scholar
• Shiran MR , ChowdryJ , Rostami-HodjeganAet al. A discordance between cytochrome P450 2D6 genotype and phenotype in patients undergoing methadone maintenance treatment . Br. J. Clin. Pharmacol.56 ( 2 ), 220 – 224 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Sindrup SH , Br⊘senK , GramLFet al. The relationship between paroxetine and the sparteine oxidation polymorphism . Clin. Pharmacol. Ther.51 ( 3 ), 278 – 287 ( 1992 ).
   PubMed Web of Science ®Google Scholar
• Jeppesen U , GramLF , VistisenK , LoftS , PoulsenHE , Br⊘senK . Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine . Eur. J. Clin. Pharmacol.51 ( 1 ), 73 – 78 ( 1996 ).
   PubMed Web of Science ®Google Scholar
• Alfaro CL , LamYW , SimpsonJ , EreshefskyL . CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline . J. Clin. Psychopharmacol.19 ( 2 ), 155 – 163 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Alfaro CL , LamYW , SimpsonJ , EreshefskyL . CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: intraindividual variability and plasma concentration correlations . J. Clin. Pharmacol.40 ( 1 ), 58 – 66 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Zourková A , HadasováE . Paroxetine-induced conversion of cytochrome P450 2D6 phenotype and occurence of adverse effects . Gen. Physiol. Biophys.22 ( 1 ), 103 – 113 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Brinn R , Br⊘senK , GramLF , HaghfeltT , OttonSV . Sparteine oxidation is practically abolished in quinidine-treated patients . Br. J. Clin. Pharmacol.22 ( 2 ), 194 – 197 ( 1986 ).
   PubMed Web of Science ®Google Scholar
• Br⊘sen K , GramLF , HaghfeltT , BertilssonL . Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatment . Pharmacol. Toxicol.60 ( 4 ), 312 – 314 ( 1987 ).
   PubMedGoogle Scholar
• Ayesh R , DawlingS , HaylerAet al. Comparative effects of the diastereoisomers, quinine and quinidine in producing phenocopy debrisoquine poor metabolisers (PMs) in healthy volunteers . Chirality3 ( 1 ), 14 – 18 ( 1991 ).
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman SM , GotschallRR , KauffmanRE , LeederJS , KearnsGL . Investigation of terbinafine as a CYP2D6 inhibitor In vivo . Clin. Pharmacol. Ther.65 ( 5 ), 465 – 472 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Cai WM , ChenB , LingSS , ZhangYD . Terbinafine-associated inhibition of dextromethorphan metabolism in Chinese subjects . Br. J. Clin. Pharmacol.51 ( 1 ), 107 – 108 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• LLerena A , BereczR , de la RubiaA , Fernández-SalgueroP , DoradoP . Effect of thioridazine dosage on the debrisoquine hydroxylation phenotype in psychiatric patients with different CYP2D6 genotypes . Ther. Drug Monit.23 ( 6 ), 616 – 620 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• LLerena A , HerraízAG , CobaledaJ , JohanssonI , DahlML . Debrisoquin and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents . Clin. Pharmacol. Ther.54 ( 6 ), 606 – 611 ( 1993 ).
   PubMed Web of Science ®Google Scholar
• Ieiri I , YamadaS , SetoKet al. A CYP2D6 phenotype–genotype mismatch in Japanese psychiatric patients . Pharmacopsychiatry36 ( 5 ), 192 – 196 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Köhler D , HärtterS , FuchsK , SieghartW , HiemkeC . CYP2D6 genotype and phenotyping by determination of dextromethorphan and metabolites in serum of healthy controls and of patients under psychotropic medication . Pharmacogenetics7 ( 6 ), 453 – 461 ( 1997 ).
   PubMedGoogle Scholar
• de Leon J , SusceMT , PanRM , WedlundPJ , OrregoML , DiazFJ . A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels . Pharmacopsychiatry40 ( 3 ), 93 – 102 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• O’Neil WM , GilfixBM , MarkoglouN , Di GirolamoA , TsoukasCM , WainerIW . Genotype and phenotype of cytochrome P450 2D6 in human immunodeficiency virus-positive patients and patients with acquired immunodeficiency syndrome . Eur. J. Clin. Pharmacol.56 ( 3 ), 231 – 240 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Jones AE , BrownKC , WernerREet al. Variability in drug metabolizing enzyme activity in HIV-infected patients . Eur. J. Clin. Pharmacol.66 ( 5 ), 475 – 485 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Girardin F , DaaliY , Gex-FabryMet al. for Swiss Hepatitis C Cohort Study Group . Liver kidney microsomal type 1 antibodies reduce the CYP2D6 activity in patients with chronic hepatitis C virus infection . J. Viral Hepat.19 ( 8 ), 568 – 573 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Williams ML , BhargavaP , CherroukI , MarshallJL , FlockhartDA , WainerIW . A discordance of the cytochrome P450 2C19 genotype and phenotype in patients with advanced cancer . Br. J. Clin. Pharmacol.49 ( 5 ), 485 – 488 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Helsby NA , LoWY , SharplesKet al. CYP2C19 pharmacogenetics in advanced cancer: compromised function independent of genotype . Br. J. Cancer99 ( 8 ), 1251 – 1255 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Burns KE , GoldthorpeMA , PorteusF , BrowettP , HelsbyNA . CYP2C19 genotype–phenotype discordance in patients with multiple myeloma leads to an acquired loss of drug-metabolising activity . Cancer Chemother. Pharmacol.73 ( 3 ), 651 – 655 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Rost KL , BrockmöllerJ , EsdornF , RootsI . Phenocopies of poor metabolizers of omeprazole caused by liver disease and drug treatment . J. Hepatol.23 ( 3 ), 268 – 277 ( 1995 ).
   PubMed Web of Science ®Google Scholar
• Borges S , DestaZ , JinYet al. Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients . J. Clin. Pharmacol.50 ( 4 ), 450 – 458 ( 2010 ). Erratum in: J. Clin. Pharmacol. 50(6), 725 (2010) .
   PubMed Web of Science ®Google Scholar
• Rogers HL , BhattaramA , ZinehIet al. CYP2D6 genotype information to guide pimozide treatment in adult and pediatric patients: basis for the U.S. Food and Drug Administration’s new dosing recommendations . J. Clin. Psychiatry73 ( 9 ), 1187 – 1190 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Medical review (NUEDEXTA) . Food and Drug Administration, Silver Spring , Maryland, USA , 29 October 2010 . www.accessdata.fda.gov/drugsatfda_docs/nda/2010/021879Orig1s000MedR.pdf .
   Google Scholar
• Food and Drug Administration. Drug label for BRISDELLE (paroxetine mesylate) dated 1 December . Food and Drug Administration, Silver Spring , Maryland, USA . www.accessdata.fda.gov/drugsatfda_docs/label/2014/204516s003lbl.pdf .
   Google Scholar
• Hertz DL , McLeodHL , IrvinWJJr . Tamoxifen and CYP2D6: a contradiction of data . Oncologist17 ( 5 ), 620 – 630 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Andersson ML , LindhJD , MannheimerB . The impact of interacting drugs on dispensed doses of warfarin in the Swedish population: a novel use of population based drug registers . J. Clin. Pharmacol.53 ( 12 ), 1322 – 1327 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Santos PC , SoaresRA , StrunzCMet al. Simultaneous use of amiodarone influences warfarin maintenance dose but is not associated with adverse events . J. Manag. Care Spec. Pharm.20 ( 4 ), 376 – 381 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Morgan ET . Regulation of cytochromes P450 during inflammation and infection . Drug Metab. Rev.29 ( 4 ), 1129 – 1188 ( 1997 ).
   PubMed Web of Science ®Google Scholar
• Renton KW . Cytochrome P450 regulation and drug biotransformation during inflammation and infection . Curr. Drug Metab.5 ( 3 ), 235 – 243 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Aitken AE , MorganET . Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes . Drug Metab. Dispos.35 ( 9 ), 1687 – 1693 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Christensen H , HermannM . Immunological response as a source to variability in drug metabolism and transport . Front. Pharmacol.3 , 8 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Zanger UM , SchwabM . Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation . Pharmacol. Ther.138 ( 1 ), 103 – 141 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Rieger JK , ReutterS , HofmannU , SchwabM , ZangerUM . Inflammation-associated microRNA-130b down-regulates cytochrome P450 activities and directly targets CYP2C . Drug Metab. Dispos.43 ( 6 ), 884 – 888 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• O’Neil WM , GilfixBM , DiGirolamoA , TsoukasCM , WainerIW . N-acetylation among HIV-positive patients and patients with AIDS: when is fast, fast and slow, slow?Clin. Pharmacol. Ther.62 ( 3 ), 261 – 271 ( 1997 ).
   PubMed Web of Science ®Google Scholar
• Akinyinka OO , SowunmiA , HoneywellR , RenwickAG . The pharmacokinetics of caffeine in Nigerian children suffering from malaria and kwashiorkor . Eur. J. Clin. Pharmacol.56 ( 2 ), 153 – 158 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Akinyinka OO , SowunmiA , HoneywellR , RenwickAG . The effects of acute falciparum malaria on the disposition of caffeine and the comparison of saliva and plasma-derived pharmacokinetic parameters in adult Nigerians . Eur. J. Clin. Pharmacol.56 ( 2 ), 159 – 165 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Lanchote VL , AlmeidaR , BarralAet al. Impact of visceral leishmaniasis and curative chemotherapy on cytochrome P450 activity in Brazilian patients . Br. J. Clin. Pharmacol.80 ( 5 ), 1160 – 1168 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• van Wanrooy MJ , SpanLF , RodgersMGet al. Inflammation is associated with voriconazole trough concentrations . Antimicrob. Agents Chemother.58 ( 12 ), 7098 – 7101 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Tóth K , BűdiT , KissAet al. Phenoconversion of CYP2C9 in epilepsy limits the predictive value of CYP2C9 genotype in optimizing valproate therapy . Pers. Med.12 ( 3 ), 201 – 209 ( 2015 ).
   Web of Science ®Google Scholar
• Gunes A , BilirE , ZengilH , BabaogluMO , BozkurtA , YasarU . Inhibitory effect of valproic acid on cytochrome P450 2C9 activity in epilepsy patients . Basic Clin. Pharmacol. Toxicol.100 ( 6 ), 383 – 386 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Choi J , NordliDRJr , AldenTDet al. Cellular injury and neuroinflammation in children with chronic intractable epilepsy . J. Neuroinflammation6 , 38 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Li G , BauerS , NowakMet al. Cytokines and epilepsy . Seizure20 ( 3 ), 249 – 256 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Quirico-Santos T , MeiraID , GomesACet al. Resection of the epileptogenic lesion abolishes seizures and reduces inflammatory cytokines of patients with temporal lobe epilepsy . J. Neuroimmunol.254 ( 1–2 ), 125 – 130 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Liang L , WangH , PengXY , ZhaoM . The changes of Th lymphocyte subsets in patients with Behcet disease. [Chinese]Zhonghua Yan Ke Za Zhi.47 ( 5 ), 393 – 397 ( 2011 ).
   PubMedGoogle Scholar
• Goktaş MT , HattaF , KaracaOet al. Lower CYP2C9 activity in Turkish patients with Behçet’s disease compared with healthy subjects: a down-regulation due to inflammation? Eur. J. Clin. Pharmacol. 71 ( 10 ), 1223 – 1228 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Isoherranen N , ThummelKE . Drug metabolism and transport during pregnancy: how does drug disposition change during pregnancy and what are the mechanisms that cause such changes?Drug Metab. Dispos.41 ( 2 ), 256 – 262 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Helldén A , MadadiP . Pregnancy and pharmacogenomics in the context of drug metabolism and response . Pharmacogenomics14 ( 14 ), 1779 – 1791 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Högstedt S , LindbergB , RaneA . Increased oral clearance of metoprolol in pregnancy . Eur. J. Clin. Pharmacol.24 ( 2 ), 217 – 220 ( 1983 ).
   PubMed Web of Science ®Google Scholar
• Wadelius M , DarjE , FrenneG , RaneA . Induction of CYP2D6 in pregnancy . Clin. Pharmacol. Ther.62 ( 4 ), 400 – 407 ( 1997 ).
   PubMed Web of Science ®Google Scholar
• Tracy TS , VenkataramananR , GloverDD , CaritisSN for National Institute for Child Health and Human Development Network of Maternal-Fetal-Medicine Units . Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A activity) during pregnancy . Am. J. Obstet. Gynecol.192 ( 2 ), 633 – 639 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Ryu RJ , EyalS , EasterlingTRet al. Pharmacokinetics of metoprolol during pregnancy and lactation . J. Clin. Pharmacol. doi:10.1002/jcph.631 ( 2015 ) ( Epub ahead of print ).
   Web of Science ®Google Scholar
• Kloprogge F , McGreadyR , PhyoAPet al. Opposite malaria and pregnancy effect on oral bioavailability of artesunate – a population pharmacokinetic evaluation . Br. J. Clin. Pharmacol.80 ( 4 ), 642 – 653 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Desai RJ , HuybrechtsKF , Hernandez-DiazSet al. Exposure to prescription opioid analgesics in utero and risk of neonatal abstinence syndrome: population based cohort study . Br. Med. J.350 , h2102 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Bateman BT , Hernandez-DiazS , RathmellJPet al. Patterns of opioid utilization in pregnancy in a large cohort of commercial insurance beneficiaries in the United States . Anesthesiology120 ( 5 ), 1216 – 1224 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Koren G , CairnsJ , ChitayatD , GaedigkA , LeederSJ . Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother . Lancet368 ( 9536 ), 704 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Kirchheiner J , SchmidtH , TzvetkovMet al. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication . Pharmacogenomics J.7 ( 4 ), 257 – 265 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Madadi P , CiszkowskiC , GaedigkAet al. Genetic transmission of cytochrome P450 2D6 (CYP2D6) ultrarapid metabolism: implications for breastfeeding women taking codeine . Curr. Drug Saf.6 ( 1 ), 36 – 39 ( 2011 ).
   PubMedGoogle Scholar
• Linares OA , FudinJ , SchiesserWE , Daly LinaresAL , BostonRC . CYP2D6 phenotype-specific codeine population pharmacokinetics . J. Pain Palliat. Care Pharmacother.29 ( 1 ), 4 – 15 ( 2015 ).
   PubMedGoogle Scholar
• Carrillo JA , RamosSI , HerraizAGet al. Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients . J. Clin. Psychopharmacol.19 ( 6 ), 494 – 499 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Dilger K , GreinerB , FrommMF , HofmannU , KroemerHK , EichelbaumM . Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D . Pharmacogenetics9 ( 5 ), 551 – 559 ( 1999 ).
   PubMedGoogle Scholar
• Lötsch J , RohrbacherM , SchmidtH , DoehringA , BrockmöllerJ , GeisslingerG . Can extremely low or high morphine formation from codeine be predicted prior to therapy initiation?Pain144 ( 1–2 ), 119 – 124 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Gressier F , VerstuyftC , HardyP , BecquemontL , CorrubleE . Response to CYP2D6 substrate antidepressants is predicted by a CYP2D6 composite phenotype based on genotype and comedications with CYP2D6 inhibitors . J. Neural Transm.122 ( 1 ), 35 – 42 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• de Graan AJ , TeunissenSF , de VosFYet al. Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment . J. Clin. Oncol.29 ( 24 ), 3240 – 3246 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Mürdter TE , SchrothW , Bacchus-GerybadzeLet al. Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of Phase I and II enzymes on their concentration levels in plasma . Clin. Pharmacol. Ther.89 ( 5 ), 708 – 717 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Antunes MV , LindenR , SantosTVet al. Endoxifen levels and its association with CYP2D6 genotype and phenotype: evaluation of a southern Brazilian population under tamoxifen pharmacotherapy . Ther. Drug Monit.34 ( 4 ), 422 – 431 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Opdam FL , DezentjeVO , den HartighJet al. The use of the 13C-dextromethorphan breath test for phenotyping CYP2D6 in breast cancer patients using tamoxifen: association with CYP2D6 genotype and serum endoxifen levels . Cancer Chemother. Pharmacol.71 ( 3 ), 593 – 601 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Vogl S , LutzRW , SchönfelderG , LutzWK . CYP2C9 genotype vs. metabolic phenotype for individual drug dosing – a correlation analysis using flurbiprofen as probe drug . PLoS ONE10 ( 3 ), e0120403 ( 2015 ). Correction: PLoS ONE 10(4), e0126329 (2015) .
   PubMed Web of Science ®Google Scholar
• Fuhr U , JetterA , KirchheinerJ . Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the “cocktail” approach . Clin. Pharmacol. Ther.81 ( 2 ), 270 – 283 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Ruddy KJ , DesantisSD , GelmanRSet al. Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice . Breast Cancer Res. Treat.141 ( 3 ), 421 – 427 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Antunes MV , de OliveiraV , RaymundoSet al. CYP3A4*22 is related to increased plasma levels of 4-hydroxytamoxifen and partially compensates for reduced CYP2D6 activation of tamoxifen . Pharmacogenomics16 ( 6 ), 601 – 617 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Binkhorst L , MathijssenRH , JagerA , van GelderT . Individualization of tamoxifen therapy: much more than just CYP2D6 genotyping . Cancer Treat. Rev.41 ( 3 ), 289 – 299 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Irvin WJ Jr , WalkoCM , WeckKEet al. Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study . J. Clin. Oncol.29 ( 24 ), 3232 – 3239 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Welzen ME , DezentjéVO , van SchaikRHet al. The effect of tamoxifen dose increment in patients with impaired CYP2D6 activity . Ther. Drug Monit.37 ( 4 ), 501 – 507 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Saladores P , MürdterT , EcclesDet al. Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer . Pharmacogenomics J.15 ( 1 ), 84 – 94 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Goetz MP , KnoxSK , SumanVJet al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen . Breast Cancer Res. Treat.101 ( 1 ), 113 – 121 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Ensom MH , ChangTK , PatelP . Pharmacogenetics: the therapeutic drug monitoring of the future?Clin. Pharmacokinet.40 ( 11 ), 783 – 802 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Gervasini G , BenítezJ , CarrilloJA . Pharmacogenetic testing and therapeutic drug monitoring are complementary tools for optimal individualization of drug therapy . Eur. J. Clin. Pharmacol.66 ( 8 ), 755 – 774 ( 2010 ).
   PubMed Web of Science ®Google Scholar